Kinomica develops proteomic data science platforms to advance precision cancer treatments.
Kinomica is a proteomic data science and diagnostics company that develops pioneering cell signalling bioinformatics and biomarker platforms for precision medicine. Headquartered in Alderley Park, the business provides innovative tools to aid the development of kinase inhibitor drugs and cancer treatments.
Shareholders' funds
Profit for the year
Employees
Cash, assets and headcount from Kinomica's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Pedro Cutillas
Professor of Cell Signalling and Proteomics
Pedro brings academic research experience from the Barts Cancer Institute and Imperial College, alongside co-founding Kinomica. He currently serves as a profesor de investigación.
LinkedInThe seed round was co-led by BGF and Longwall Venture Partners with participation from seed backers including BioCity, Alderley Park Ventures, and Puffin Point.
